This video examines the promise of recent trials studying single-agent immunotherapy as well as ongoing trials testing combinations of immune-checkpoint inhibition.
Anti–CTLA-4 and anti–PD-1 checkpoint inhibitors have both shown promise in the treatment of hepatocellular carcinoma (HCC).
In this video, Ghassan K. Abou-Alfa, MD, of Memorial Sloan Kettering Cancer Center in New York, discusses the promise of recent trials that have studied single-agent immunotherapy and ongoing trials testing combinations of immunotherapies and immune-checkpoint inhibition in different lines of treatment.
Abou-Alfa also highlights the latest results in second-line HCC treatment using the multikinase inhibitor regorafenib, and looks ahead at trials involving c-MET inhibition for patients with HCC.
Oncology On-The-Go Podcast: ASCO 2023 Recap
June 19th 2023Experts from University of California, Los Angeles Health and Mayo Clinic discuss key data presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting in the gynecologic and gastrointestinal cancer spaces and how they may impact patient care.
FDA Updates Indication for Pembrolizumab in HER2+ Gastric/GEJ Adenocarcinoma
November 9th 2023Only patients with PD-L1–positive tumors may receive treatment with pembrolizumab plus trastuzumab and chemotherapy for HER2-positive gastric or gastroesophageal junction adenocarcinoma following the FDA’s amendment.
Domvanalimab Plus Zimberelimab Improve Efficacy in Gastrointestinal Cancers
November 7th 2023Results from arm A1 of the phase 2 EDGE-Gastric study indicate that patients with gastric, gastroesophageal junction, and esophageal adenocarcinoma experienced improved responses after receiving domvanalimab/zimberelimab.